Bright Minds BiosciencesNASDAQ: DRUG
Bright Minds Biosciences (NASDAQ: DRUG) is a Vancouver-based biotech developing highly selective serotonergic agonists for neurological and psychiatric disorders. Lead asset BMB-101, a 5-HT2C agonist, is in Phase 2 for drug-resistant epilepsy (BREAKTHROUGH study, positive Phase 2 results January 2026). BMB-201 is a 5-HT2A/2C agonist showing preclinical efficacy in pain and migraine models (outperformed sumatriptan, Sept 2025). BMB-202 is a selective 5-HT2A agonist with antidepressant profile in development for MDD.
Drug Pipeline
3BMB-101
5-HT2C agonist for drug-resistant absence epilepsy and DEE. BREAKTHROUGH Phase 2 study: 73% median reduction in absence seizures (n=11). Positive topline results Jan 2026.
BMB-201
5-HT2A/2C mixed agonist (prodrug of BMB-A39a). Outperformed sumatriptan in vascular headache model (Sept 2025) and showed morphine-equivalent efficacy in pain models.
BMB-202
Highly selective 5-HT2A agonist (500-fold selectivity over 5-HT2B). Fast-on-fast-off kinetics; antidepressant profile in vivo. First clinical candidate from phenethylamine scaffold series.
Quick Facts
- Type
- Public Biotech
- Ticker
- NASDAQ: DRUG
- Lead Stage
- Phase II
- Website
- Visit